Ximelagatranum Uses, Dosage, Side Effects and more
Ximelagatranum is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries where the drug had been approved.
| Trade Name | Ximelagatranum |
| Generic | Ximelagatran |
| Ximelagatran Other Names | Ximelagatrán, Ximelagatran, Ximélagatran, Ximelagatranum |
| Type | |
| Formula | C24H35N5O5 |
| Weight | Average: 473.5652 Monoisotopic: 473.263819255 |
| Groups | Approved, Investigational, Withdrawn |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
For the treatment of acute deep vein thrombosis.
How Ximelagatranum works
Ximelagatranum was the first member of the drug class of direct thrombin inhibitors that can be taken orally. Its effect is solely related to the inhibition of thrombin.
Toxicity
Hepatotoxicity (liver damage) was reported during trials.
Food Interaction
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
Elimination Route
Rapidly absorbed by the small intestine with an oral bioavailability of 20%.
Half Life
3-5 hours
